Targeted treatment in patients with non-small cell lung cancer: Use of Bevacizumab and its Biosimilars
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021.
| מחבר ראשי: | |
|---|---|
| מחברים אחרים: | |
| פורמט: | Thesis |
| שפה: | English |
| יצא לאור: |
Brac University
2023
|
| נושאים: | |
| גישה מקוונת: | http://hdl.handle.net/10361/18736 |
| id |
10361-18736 |
|---|---|
| record_format |
dspace |
| spelling |
10361-187362023-07-11T21:05:03Z Targeted treatment in patients with non-small cell lung cancer: Use of Bevacizumab and its Biosimilars Tania, Umme Khan, Tanisha Kabir, Dr. Eva Rahman Department of Pharmacy, Brac University Biologics Biosimilars Bevacizumab Non-small cell lung cancer Regulatory frameworks Targeted therapy Lungs--Cancer This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021. Cataloged from PDF version of thesis. Includes bibliographical references (pages 53-61). Angiogenesis is one of the pivotal factors contributing to the development and metastasis of non small cell lung cancer which is one of the most commonly diagnosed types of lung cancer. Bevacizumab, a monoclonal antibody that acts by restricting angiogenesis, is therefore a major choice of medication for advanced and metastatic non-small cell lung cancer treatment. Bevacizumab is essentially a biologic medicine which is a distinct class of biopharmaceuticals. Biologics are considerably expensive and this has resulted in the advent of biosimilars which are highly similar to their reference biologics in terms of quality, efficacy, and safety. As biosimilars are adopted as affordable copies of biologics, they possess great potential to influence the healthcare system. In this literature review, the importance of biosimilars with respect to its cost effectiveness and accessibility to the patients were discussed. The study also focused on the availability of biosimilars of bevacizumab as a potential targeted treatment option for NSCLC. In the meantime, regulatory frameworks established in different countries concerning the introduction of biosimilars in the market were reviewed. Umme Tania B. Pharmacy 2023-07-11T08:42:36Z 2023-07-11T08:42:36Z 2021 2021-04 Thesis ID: 17346054 http://hdl.handle.net/10361/18736 en Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 61 pages application/pdf Brac University |
| institution |
Brac University |
| collection |
Institutional Repository |
| language |
English |
| topic |
Biologics Biosimilars Bevacizumab Non-small cell lung cancer Regulatory frameworks Targeted therapy Lungs--Cancer |
| spellingShingle |
Biologics Biosimilars Bevacizumab Non-small cell lung cancer Regulatory frameworks Targeted therapy Lungs--Cancer Tania, Umme Targeted treatment in patients with non-small cell lung cancer: Use of Bevacizumab and its Biosimilars |
| description |
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021. |
| author2 |
Khan, Tanisha |
| author_facet |
Khan, Tanisha Tania, Umme |
| format |
Thesis |
| author |
Tania, Umme |
| author_sort |
Tania, Umme |
| title |
Targeted treatment in patients with non-small cell lung cancer: Use of Bevacizumab and its Biosimilars |
| title_short |
Targeted treatment in patients with non-small cell lung cancer: Use of Bevacizumab and its Biosimilars |
| title_full |
Targeted treatment in patients with non-small cell lung cancer: Use of Bevacizumab and its Biosimilars |
| title_fullStr |
Targeted treatment in patients with non-small cell lung cancer: Use of Bevacizumab and its Biosimilars |
| title_full_unstemmed |
Targeted treatment in patients with non-small cell lung cancer: Use of Bevacizumab and its Biosimilars |
| title_sort |
targeted treatment in patients with non-small cell lung cancer: use of bevacizumab and its biosimilars |
| publisher |
Brac University |
| publishDate |
2023 |
| url |
http://hdl.handle.net/10361/18736 |
| work_keys_str_mv |
AT taniaumme targetedtreatmentinpatientswithnonsmallcelllungcanceruseofbevacizumabanditsbiosimilars |
| _version_ |
1814307141425561600 |